PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
DexCom, Inc. (DXCM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US2521311074

CUSIP

252131107

Sector

Healthcare

IPO Date

Apr 14, 2005

Highlights

Market Cap

$29.04B

EPS (TTM)

$1.65

PE Ratio

45.05

PEG Ratio

1.10

Total Revenue (TTM)

$3.95B

Gross Profit (TTM)

$2.44B

EBITDA (TTM)

$940.70M

Year Range

$62.34 - $142.00

Target Price

$95.97

Short %

2.23%

Short Ratio

1.83

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
DXCM vs. PODD DXCM vs. TNDM DXCM vs. RMD DXCM vs. VRSK DXCM vs. SF DXCM vs. LLY DXCM vs. VOO DXCM vs. VYM DXCM vs. XLV DXCM vs. SCHD
Popular comparisons:
DXCM vs. PODD DXCM vs. TNDM DXCM vs. RMD DXCM vs. VRSK DXCM vs. SF DXCM vs. LLY DXCM vs. VOO DXCM vs. VYM DXCM vs. XLV DXCM vs. SCHD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in DexCom, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%JuneJulyAugustSeptemberOctoberNovember
-41.94%
10.60%
DXCM (DexCom, Inc.)
Benchmark (^GSPC)

Returns By Period

DexCom, Inc. had a return of -38.85% year-to-date (YTD) and -27.71% in the last 12 months. Over the past 10 years, DexCom, Inc. had an annualized return of 19.62%, outperforming the S&P 500 benchmark which had an annualized return of 11.16%.


DXCM

YTD

-38.85%

1M

4.84%

6M

-42.24%

1Y

-27.71%

5Y (annualized)

6.91%

10Y (annualized)

19.62%

^GSPC (Benchmark)

YTD

23.62%

1M

0.54%

6M

11.19%

1Y

30.63%

5Y (annualized)

13.61%

10Y (annualized)

11.16%

Monthly Returns

The table below presents the monthly returns of DXCM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-2.21%-5.18%20.54%-8.15%-6.77%-4.54%-40.18%2.24%-3.32%5.13%-38.85%
2023-5.43%3.66%4.66%4.44%-3.36%9.59%-3.07%-18.93%-7.61%-4.79%30.05%7.42%9.58%
2022-19.83%-3.85%23.60%-20.14%-27.08%0.06%10.13%0.16%-2.03%49.96%-3.73%-2.61%-15.64%
20211.39%6.12%-9.65%7.43%-4.33%15.60%20.73%2.70%3.29%13.96%-9.73%-4.56%45.23%
202010.06%14.64%-2.44%24.48%12.86%7.16%7.43%-2.33%-3.10%-22.48%0.03%15.65%69.02%
201917.72%-1.21%-14.52%1.65%0.19%23.53%4.69%9.40%-13.04%3.35%47.37%-3.77%82.59%
20181.41%-3.54%32.10%-1.32%20.24%7.94%0.16%51.77%-0.93%-7.18%-2.40%-7.55%108.75%
201732.58%-1.25%8.41%-7.99%-14.26%9.44%-8.94%12.01%-34.42%-8.09%29.93%-1.78%-3.87%
2016-12.97%-8.73%4.38%-5.20%0.17%23.01%16.26%-1.24%-3.77%-10.75%-16.55%-8.56%-27.11%
20158.59%1.61%2.63%8.39%6.14%11.52%5.84%11.21%-8.80%-2.96%2.04%-3.67%48.77%
201414.26%11.47%-8.29%-21.57%4.07%17.48%-4.99%17.30%-9.52%12.40%14.48%6.98%55.46%
201312.07%-2.04%12.06%-1.85%26.93%7.78%-2.98%24.20%4.33%1.81%15.18%7.01%160.56%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of DXCM is 22, indicating that it is in the bottom 22% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of DXCM is 2222
Combined Rank
The Sharpe Ratio Rank of DXCM is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of DXCM is 2424
Sortino Ratio Rank
The Omega Ratio Rank of DXCM is 2121
Omega Ratio Rank
The Calmar Ratio Rank of DXCM is 2020
Calmar Ratio Rank
The Martin Ratio Rank of DXCM is 2626
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for DexCom, Inc. (DXCM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for DXCM, currently valued at -0.47, compared to the broader market-4.00-2.000.002.004.00-0.472.51
The chart of Sortino ratio for DXCM, currently valued at -0.24, compared to the broader market-4.00-2.000.002.004.00-0.243.37
The chart of Omega ratio for DXCM, currently valued at 0.95, compared to the broader market0.501.001.502.000.951.47
The chart of Calmar ratio for DXCM, currently valued at -0.42, compared to the broader market0.002.004.006.00-0.423.63
The chart of Martin ratio for DXCM, currently valued at -0.88, compared to the broader market0.0010.0020.0030.00-0.8816.15
DXCM
^GSPC

The current DexCom, Inc. Sharpe ratio is -0.47. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of DexCom, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.47
2.48
DXCM (DexCom, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


DexCom, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-53.39%
-2.18%
DXCM (DexCom, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the DexCom, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the DexCom, Inc. was 94.61%, occurring on Nov 20, 2008. Recovery took 1185 trading sessions.

The current DexCom, Inc. drawdown is 53.39%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.61%May 5, 2006643Nov 20, 20081185Aug 8, 20131828
-60.69%Nov 18, 2021674Jul 26, 2024
-56.37%Sep 18, 2015532Oct 26, 2017176Jul 11, 2018708
-39.59%Mar 6, 201444May 7, 2014129Nov 7, 2014173
-36.81%Feb 21, 202019Mar 18, 202020Apr 16, 202039

Volatility

Volatility Chart

The current DexCom, Inc. volatility is 9.61%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%JuneJulyAugustSeptemberOctoberNovember
9.61%
4.06%
DXCM (DexCom, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of DexCom, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of DexCom, Inc. compared to its peers in the Diagnostics & Research industry.


PE Ratio
50.0100.0150.0200.0250.0300.045.1
The chart displays the price to earnings (P/E) ratio for DXCM in comparison to other companies of the Diagnostics & Research industry. Currently, DXCM has a PE value of 45.1. This PE ratio falls in the average range for the industry.
PEG Ratio
-2.00.02.04.01.1
The chart displays the price to earnings to growth (PEG) ratio for DXCM in comparison to other companies of the Diagnostics & Research industry. Currently, DXCM has a PEG value of 1.1. This PEG ratio falls in the average range for the industry.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for DexCom, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items